Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01852708 · ClinicalTrials.gov registry record

Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood

A clinical trial of Trisomy 21 and Trisomy 18, sponsored by Natera.

Completed
Registry status
1,059
Enrollment target
9
Study locations

NCT01852708 is a study of Trisomy 21 and Trisomy 18 that has completed, run by Natera. The registered enrollment target is 1,059 participants, above the 655-participant average among 5 other Trisomy 21 trials with a reported enrollment target (62% higher). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01852708, a study of Trisomy 21 and Trisomy 18, has completed, sponsored by Natera.

COMPLETED
Registry status
1,059 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this study is to collect maternal blood samples from pregnant women carrying a fetus with a confirmed diagnosis of chromosomal abnormality or genetic disorder including microdeletions in order to further develop a non-invasive prenatal screening test based on fetal DNA isolated from maternal blood.

Study Locations (9)

California

  • Natera, Inc. - San Carlos
  • MFM Group of Southern CA - San Gabriel

Other

  • Hospital Materno Infantil Vall d'Hebron - Barcelona
  • GenePhile Biosciences - Taipei

District of Columbia

  • Washington Women's Wellness Center - Washington D.C.

New Jersey

  • Saint Peter's University Hospital - New Brunswick

New York

  • Columbia University - New York

Pennsylvania

  • The Children's Hospital of Philadelphia - Philadelphia

Texas

  • Dr. Meltzer Clinic - Houston

Trial Details

FieldValue
Enrollment Target 1,059 participants
Start Date 2012-11
Est. Completion 2020-10

Sponsor

Natera

27 total trials

What the Registry Record Tells You About NCT01852708

The ClinicalTrials.gov registry entry for NCT01852708 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,059 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 655-participant average among 5 other Trisomy 21 trials with a reported enrollment target (62% higher). The listed sponsor is Natera, which has 27 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Trisomy 21 appearing as the primary indexed condition, and to 0 interventions.

NCT01852708 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, Other, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT01852708 about?

NCT01852708 is a clinical study titled "Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood". The purpose of this study is to collect maternal blood samples from pregnant women carrying a fetus with a confirmed diagnosis of chromosomal abnormality or genetic disorder including microdeletions in order to further develop a non-invasive prenatal screening test based on fetal DNA isolated from m...

What is the current status of trial NCT01852708?

This trial is currently completed. The enrollment target is 1,059 participants. The study started on 2012-11. Estimated completion is 2020-10.

What conditions does trial NCT01852708 study?

This clinical trial studies the following conditions: Trisomy 21, Trisomy 18, Trisomy 13, Sex Chromosome Abnormalities, Microdeletion Syndromes.

Who is sponsoring clinical trial NCT01852708?

This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01852708 being conducted?

This trial has 9 study locations across California, District of Columbia, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Trisomy 21

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.